Skin cancer deaths among men are on the rise. A dermatologist explains the reasons why, and what we can do about it.
Skin Cancer Information
Immunotherapy, unlike traditional cancer treatments like chemotherapy, does not kill cancer cells with an outside drug. The therapy is designed to inspire the body’s own defenses to take out cancer.
If you (or someone you know) has been diagnosed with two or more nonmelanoma skin cancers, you are part of a special group. You are also, unfortunately, at much higher risk of developing further skin cancers. Here’s why — and what you can do about it.
Our authors’ recent research shows that melanoma in situ, the earliest form of the disease, is on the rise, especially among young men. Here’s why this is bad news and good news, and what everyone (not just the men) needs to know to stay ahead of it.
While physicians commonly use Mohs surgery or excisional surgery to remove skin cancer, additional steps may be required to fully reconstruct the surgical site. One way physicians close a surgical area is by using surrounding tissue, also called flap surgery.
All melanomas are associated with an initial tumor, but sometimes the location is difficult to ascertain.
You may have heard about a new medication that was recently FDA approved for cutaneous squamous cell carcinoma (CSCC). Libtayo (cemiplimab-rwlc) is a type of immunotherapy called a checkpoint blockade inhibitor, and it’s the first one approved to treat certain cases of CSCC. This is exciting news, so let’s break down how this new drug works and whom it might help.